US-based medical technology company SonaCare Medical has entered into a marketing alliance with Invivo to facilitate a better tracking of appropriate targets for prostate high-intensity focused ultrasound (HIFU) ablation.

Under the alliance, SonaCare Medical has assumed the licensing rights of Invivo’s UroNav fusion software, which has been integrated by both the company’s engineers with the Sonablate planning system, a product of SonaCare.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The integration allows urologists who have used UroNav to annotate and biopsy targeted prostate tissue, to detect the specific tissue appropriate for ablation directly in the Sonablate software.

"Achieving compatibility between our respective products provides Sonablate customers with much easier access to Invivo’s integrated portfolio of Prostate Oncology Solutions"

The Sonablate is a next generation software for ablation of prostate tissue. It delivers precise and focused ablation.

It is driven by the A3 Technology which allows physicians to target specific tissue using integrated ultrasound imaging and sophisticated planning tools; ablate targeted tissue with HIFU ablation that offers accuracy while sparing untargeted tissue.

See Also:

Following its FDA approval, the software has been used by 15,000 patients in more than 30 countries.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The alliance also entitles Invivo to sell Sonablate to almost 200 UroNav facilities in the US.

Invivo strategy and business development senior director Thomas Tynes said: "Achieving compatibility between our respective products provides Sonablate customers with much easier access to Invivo’s integrated portfolio of Prostate Oncology Solutions, including our market-leading UroNav Fusion Biopsy System.

"We look forward to working together with SonaCare to provide our customers and their patients with innovative clinical solutions throughout the care continuum."